Reductions in hemoglobin and packed cell volume over 3 years in UKPDS patients with newly diagnoses Type 2 Diabetes

Reductions in hemoglobin and packed cell volume over 3 years in UKPDS patients with newly diagnoses Type 2 Diabetes

Diabetes increases the risk for developing anemia by 2-3 fold, compared to those without diabetes and similar renal function. We examined hemoglobin (Hb) and packed cell volume (PCV) changes over three years in UK Prospective Diabetes Study (UKPDS) patients with newly-diagnosed type 2 diabetes rando...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Coleman, R
Formáid:	Conference item
Foilsithe / Cruthaithe:	American Diabetes Association 2016

Míreanna comhchosúla

Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.
de réir: Davis, T, et al.
Foilsithe / Cruthaithe: (2013)

Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89
de réir: Wamil, M, et al.
Foilsithe / Cruthaithe: (2021)

Cardiovascular Risk Assessment with Vascular Function, Carotid Atherosclerosis and the UKPDS Risk Engine in Korean Patients with Newly Diagnosed Type 2 Diabetes
de réir: Choon Sik Seon, et al.
Foilsithe / Cruthaithe: (2011-12-01)

Plasma lipids and hypoglycaemic therapies over 6 years in Type 2 diabetic patients in the UKPDS
de réir: Cull, C, et al.
Foilsithe / Cruthaithe: (1999)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
de réir: Matthews, DR, et al.
Foilsithe / Cruthaithe: (1998)

Incident nephropathy in type 2 diabetes: a UKPDS Risk Equation
de réir: Coleman, R, et al.
Foilsithe / Cruthaithe: (2005)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
de réir: Cull, C, et al.
Foilsithe / Cruthaithe: (2000)

Hypoglycaemia in patients with Type 2 diabetes in the UKPDS
de réir: Cull, C, et al.
Foilsithe / Cruthaithe: (2001)

Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).
de réir: Davis, T, et al.
Foilsithe / Cruthaithe: (2005)

The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).
de réir: Stevens, R, et al.
Foilsithe / Cruthaithe: (2001)

Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).
de réir: Kohner, E, et al.
Foilsithe / Cruthaithe: (2001)

Parathyroid Hormone is Negatively Correlated with Glycated Hemoglobin in Newly Diagnosed Type 2 Diabetic Patients
de réir: Xueqing He, et al.
Foilsithe / Cruthaithe: (2024-01-01)

The clinical value of glycosylated hemoglobin level in newly diagnosed ketosis-prone type 2 diabetes
de réir: Rui Min, et al.
Foilsithe / Cruthaithe: (2023-11-01)

UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.
de réir: Stratton, I, et al.
Foilsithe / Cruthaithe: (2001)

Estimating risk of clinically evident neuropathy in Type 2 diabetes: a UKPDS risk equation
de réir: Coleman, R, et al.
Foilsithe / Cruthaithe: (2006)

Estimating cardiovascular disease risk for individuals with Type 2 diabetes: the new UKPDS Risk Engine
de réir: Coleman, R, et al.
Foilsithe / Cruthaithe: (2007)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
de réir: Matthews, DR, et al.
Foilsithe / Cruthaithe: (1998)

Forecasting coronary case fatality in type 2 diabetes: a UKPDS Risk Engine equation
de réir: Stevens, R, et al.
Foilsithe / Cruthaithe: (2002)

Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
de réir: Cull, C, et al.
Foilsithe / Cruthaithe: (2004)

Ethnic differences in diabetic nephropathy - The UKPDS
de réir: Stevens, R, et al.
Foilsithe / Cruthaithe: (1999)

The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).
de réir: Alva, M, et al.
Foilsithe / Cruthaithe: (2014)

Ethnicity and long-term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83).
de réir: Davis, T, et al.
Foilsithe / Cruthaithe: (2014)

Ethnicity and long-term vascular outcomes in Type 2 diabetes: A prospective observational study (UKPDS 83)
de réir: Davis, T, et al.
Foilsithe / Cruthaithe: (2014)

Framingham equations underestimate cardiovascular risk compared with the UKPDS risk engine in people with Type 2 diabetes
de réir: Price, H, et al.
Foilsithe / Cruthaithe: (2007)

Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
de réir: Wright, A, et al.
Foilsithe / Cruthaithe: (2002)

RETINOPATHY IN THE UKPDS TRIAL MICRO-ANEURYSM COUNTS AND THE RISKS OF PROGRESSION OVER 3-YEARS AND 6-YEARS
de réir: Matthews, D, et al.
Foilsithe / Cruthaithe: (1995)

Estimating cardiovascular risk and all-cause mortality in individuals with type 2 diabetes using the UKPDS Outcomes Model
de réir: Coleman, RL, et al.
Foilsithe / Cruthaithe: (2019)

A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
de réir: Clarke, P, et al.
Foilsithe / Cruthaithe: (2004)

Early Glycosylated Hemoglobin Target Achievement Predicts Clinical Outcomes in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
de réir: Joonyub Lee, et al.
Foilsithe / Cruthaithe: (2021-05-01)

Early Glycosylated Hemoglobin Target Achievement Predicts Clinical Outcomes in Patients with Newly Diagnosed Type 2 Diabetes Mellitus
de réir: Joonyub Lee, et al.
Foilsithe / Cruthaithe: (2021-07-01)

Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.
de réir: Stevens, R, et al.
Foilsithe / Cruthaithe: (2004)

Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)
de réir: Adler, AI, et al.
Foilsithe / Cruthaithe: (2024)

UKPDS: Plasma leptin, obesity and plasma insulin in type 2 diabetic subjects
de réir: Widjaja, A, et al.
Foilsithe / Cruthaithe: (1996)

Plasma homocysteine, type 2 diabetes and risk of coronary heart disease in the UKPDS
de réir: Holman, R, et al.
Foilsithe / Cruthaithe: (2001)

Genetics: how the UKPDS contributed to determining the genetic landscape of Type 2 diabetes.
de réir: Gloyn, A, et al.
Foilsithe / Cruthaithe: (2008)

Inaugural Conference: UKPDS Legacy and Precision Therapy for Type 2 Diabetes Mellitus
de réir: Rury Holman
Foilsithe / Cruthaithe: (2022-09-01)

Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88
de réir: Lind, M, et al.
Foilsithe / Cruthaithe: (2021)

UKPDS - 6-YEAR TRIAL OF SULFONYLUREA, INSULIN AND METFORMIN THERAPY IN TYPE-2 DIABETIC-PATIENTS WITH DIET FAILURE
de réir: Cull, C, et al.
Foilsithe / Cruthaithe: (1995)

Ukpds risk engine
de réir: Daniel Pinto
Foilsithe / Cruthaithe: (2011-01-01)

UKPDS: what was the question? UK Prospective Diabetes Study.
de réir: Turner, R, et al.
Foilsithe / Cruthaithe: (1999)